Literature DB >> 28813656

Fcγ Receptor Function and the Design of Vaccination Strategies.

Stylianos Bournazos1, Jeffrey V Ravetch2.   

Abstract

Through specific interactions with distinct types of Fcγ receptors (FcγRs), the Fc domain of immunoglobulin G (IgG) mediates a wide spectrum of immunological functions that influence both innate and adaptive responses. Recent studies indicate that IgG Fc-FcγR interactions are dynamically regulated during an immune response through the control of the Fc-associated glycan structure and Ig subclass composition on the one hand and selective FcγR expression on immune cells on the other, which together determine the capacity of IgG to interact in a cell-type-specific manner with specific members of the FcγR family. Here, we present a framework that synthesizes the current understanding of the contribution of FcγR pathways to the induction and regulation of antibody and T cell responses. Within this context, we discuss vaccination strategies to elicit broad and potent immune responses based on the immunomodulatory properties of Fc-FcγR interactions.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  antibodies; effector functions; immune regulation; immunity; immunization; therapy; vaccination

Mesh:

Substances:

Year:  2017        PMID: 28813656      PMCID: PMC5573140          DOI: 10.1016/j.immuni.2017.07.009

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  99 in total

1.  Molecular basis for immune complex recognition: a comparison of Fc-receptor structures.

Authors:  P Sondermann; J Kaiser; U Jacob
Journal:  J Mol Biol       Date:  2001-06-08       Impact factor: 5.469

2.  Divergent immunoglobulin g subclass activity through selective Fc receptor binding.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2005-12-02       Impact factor: 47.728

3.  Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.

Authors:  Yoshikatsu Kaneko; Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2006-08-04       Impact factor: 47.728

4.  Identification of a receptor required for the anti-inflammatory activity of IVIG.

Authors:  Robert M Anthony; Fredrik Wermeling; Mikael C I Karlsson; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-26       Impact factor: 11.205

5.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

Authors:  Guillaume Cartron; Laurent Dacheux; Gilles Salles; Philippe Solal-Celigny; Pierre Bardos; Philippe Colombat; Hervé Watier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

6.  Molecular analysis of the modulatory factors of the response to HBsAg in mice as an approach to HBV vaccine enhancement.

Authors:  P Bouige; S Iscaki; A Cosson; J Pillot
Journal:  FEMS Immunol Med Microbiol       Date:  1996-01

7.  GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.

Authors:  Christian A Gerdes; Valeria Gonzalez Nicolini; Sylvia Herter; Erwin van Puijenbroek; Sabine Lang; Michaela Roemmele; Ekkehard Moessner; Olivier Freytag; Thomas Friess; Carola H Ries; Birgit Bossenmaier; Hans Joachim Mueller; Pablo Umaña
Journal:  Clin Cancer Res       Date:  2012-12-03       Impact factor: 12.531

Review 8.  The coordination of signaling during Fc receptor-mediated phagocytosis.

Authors:  Joel A Swanson; Adam D Hoppe
Journal:  J Leukoc Biol       Date:  2004-10-05       Impact factor: 4.962

9.  General mechanism for modulating immunoglobulin effector function.

Authors:  Peter Sondermann; Andrew Pincetic; Jad Maamary; Katja Lammens; Jeffrey V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-22       Impact factor: 11.205

10.  Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.

Authors:  Dan H Barouch; James B Whitney; Brian Moldt; Florian Klein; Thiago Y Oliveira; Jinyan Liu; Kathryn E Stephenson; Hui-Wen Chang; Karthik Shekhar; Sanjana Gupta; Joseph P Nkolola; Michael S Seaman; Kaitlin M Smith; Erica N Borducchi; Crystal Cabral; Jeffrey Y Smith; Stephen Blackmore; Srisowmya Sanisetty; James R Perry; Matthew Beck; Mark G Lewis; William Rinaldi; Arup K Chakraborty; Pascal Poignard; Michel C Nussenzweig; Dennis R Burton
Journal:  Nature       Date:  2013-10-30       Impact factor: 49.962

View more
  69 in total

Review 1.  Updates on antibody functions in Mycobacterium tuberculosis infection and their relevance for developing a vaccine against tuberculosis.

Authors:  Jacqueline M Achkar; Rafael Prados-Rosales
Journal:  Curr Opin Immunol       Date:  2018-04-12       Impact factor: 7.486

2.  A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection.

Authors:  Takuya Yamamoto; Yuji Masuta; Masatoshi Momota; Masaru Kanekiyo; Tomohiro Kanuma; Shoukichi Takahama; Eiko Moriishi; Yasuhiro Yasutomi; Takashi Saito; Barney S Graham; Yoshimasa Takahashi; Ken J Ishii
Journal:  Int Immunol       Date:  2019-02-15       Impact factor: 4.823

3.  A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model.

Authors:  Rohan Keshwara; Katie R Hagen; Tiago Abreu-Mota; Amy B Papaneri; David Liu; Christoph Wirblich; Reed F Johnson; Matthias J Schnell
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

Review 4.  Antibody-dependent cellular cytotoxicity in HIV infection.

Authors:  Donald N Forthal; Andrés Finzi
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

5.  Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics.

Authors:  Katie L Winarski; Juanjie Tang; Laura Klenow; Jeehyun Lee; Elizabeth M Coyle; Jody Manischewitz; Hannah L Turner; Kazuyo Takeda; Andrew B Ward; Hana Golding; Surender Khurana
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-11       Impact factor: 11.205

6.  Striking a balance in an antibody network: A roadmap for HIV-1 vaccines.

Authors:  Tysheena P Charles; Cynthia A Derdeyn
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

7.  Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.

Authors:  Natalia A Kuzmina; Patrick Younan; Pavlo Gilchuk; Rodrigo I Santos; Andrew I Flyak; Philipp A Ilinykh; Kai Huang; Ndongala M Lubaki; Palaniappan Ramanathan; James E Crowe; Alexander Bukreyev
Journal:  Cell Rep       Date:  2018-08-14       Impact factor: 9.423

8.  Porcine FcεRI Mediates Porcine Reproductive and Respiratory Syndrome Virus Multiplication and Regulates the Inflammatory Reaction.

Authors:  Peidian Shi; Lilin Zhang; Jiashun Wang; Dong Lu; Yi Li; Jie Ren; Menglu Shen; Lei Zhang; Jinhai Huang
Journal:  Virol Sin       Date:  2018-05-14       Impact factor: 4.327

9.  Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.

Authors:  Scott D Neidich; Youyi Fong; Shuying S Li; Daniel E Geraghty; Brian D Williamson; William Chad Young; Derrick Goodman; Kelly E Seaton; Xiaoying Shen; Sheetal Sawant; Lu Zhang; Allan C deCamp; Bryan S Blette; Mengshu Shao; Nicole L Yates; Frederick Feely; Chul-Woo Pyo; Guido Ferrari; Ian Frank; Shelly T Karuna; Edith M Swann; John R Mascola; Barney S Graham; Scott M Hammer; Magdalena E Sobieszczyk; Lawrence Corey; Holly E Janes; M Juliana McElrath; Raphael Gottardo; Peter B Gilbert; Georgia D Tomaras
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

10.  ImmunoPET: Concept, Design, and Applications.

Authors:  Weijun Wei; Zachary T Rosenkrans; Jianjun Liu; Gang Huang; Quan-Yong Luo; Weibo Cai
Journal:  Chem Rev       Date:  2020-03-23       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.